Olga Petryna, MD
Rheumatology · New York, NYNPI 1386878577
Payments from drug & device makers
Across 545 payments — averaging $933.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$123K
- Mallinckrodt Hospital Products Inc.$82K
- Novartis$76K
- Amgen$69K
- Lilly USA, LLC$59K
- AstraZeneca$39K
- plus $62K from 18 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 86 | $122,557 |
| Mallinckrodt Hospital Products Inc. | 60 | $82,164 |
| Novartis | 99 | $76,246 |
| Amgen(2 entities) | 87 | $68,538 |
| Lilly USA, LLC | 56 | $58,897 |
| AstraZeneca | 36 | $38,629 |
| Mallinckrodt Enterprises LLC | 14 | $19,799 |
| Pfizer | 25 | $15,066 |
| Bristol Myers Squibb | 14 | $11,620 |
| Ultragenyx Pharmaceutical Inc. | 2 | $5,400 |
| UCB, Inc. | 3 | $4,726 |
| Sanofi | 25 | $2,444 |
| Aurinia Pharma U.S., Inc. | 11 | $956 |
| AbbVie | 4 | $468 |
| Pacira Therapeutics, Inc. | 2 | $306 |
| Janssen Scientific Affairs, LLC | 3 | $240 |
| Medexus Pharma, Inc. | 9 | $224 |
| ANI Pharmaceuticals, Inc. | 2 | $188 |
| Regeneron | 1 | $119 |
| Sanofi-aventis U.S. LLC | 2 | $112 |
| Regeneron Healthcare Solutions, Inc. | 1 | $71 |
| Biohaven Pharmaceuticals, Inc. | 1 | $55 |
| Octapharma USA, Inc. | 1 | $30 |
| GSK | 1 | $14 |
How this compares
$508,867 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in New York
- Amit SaxenaNew York$6.7M
- Robert SpieraNew York$4.3M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Laura Geraldino PardillaNew York$1.7M
- Joan BathonNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.